Ratings Demant A/S

Equities

DEMANT

DK0060738599

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:51 2024-06-07 am EDT			5-day change	1st Jan Change
334 ^DKK	+0.54%		+1.52%	+12.84%

May. 29	UK’s Competition Regulator Closes Cochlear-Demant Deal	MT
May. 21	Denmark's Demant Completes Sale of Cochlear Implants Business	MT

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
With a 2024 P/E ratio at 23.72 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
With an enterprise value anticipated at 3.71 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DEMANT A/S	+12.84%	10.53B		B-
SONOVA HOLDING AG	+5.10%	19.18B		A
COCHLEAR LIMITED	+11.18%	14.32B		B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	+42.34%	1.97B		-
EMBLA MEDICAL HF.	-3.83%	1.63B		B+
ANGELALIGN TECHNOLOGY INC.	+9.55%	1.34B		D-
MODERN DENTAL GROUP LIMITED	+3.95%	542M		-
ANGEL ROBOTICS CO., LTD.	0.00%	407M	-	-
DELCATH SYSTEMS, INC.	+57.45%	182M		-
INTEGRUM AB	+20.04%	95.85M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes